Ümit Tural

Dr. Ümit Tural

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2006 in Social Psychiatry and Psychiatric Epidemiology
Verified
Journal Article
Closed access
PDF file
EÖEmin Önder
Emin Önder
ÜTÜmit Tural
Ümit Tural
TATamer Aker
Tamer Aker
CKCengiz Kılıç
Cengiz Kılıç
SESarper Erdoğan
Sarper Erdoğan

17 February 2019 in Nordic Journal of Psychiatry
Verified
Journal Article
Closed access
EEEyup Sabri Ercan
Eyup Sabri Ercan
GPGuilherme Polanczyk
Guilherme Polanczyk
UAUlku Akyol Ardıc
Ulku Akyol Ardıc
DYDeniz Yuce
Deniz Yuce
GKGul Karacetın
Gul Karacetın
NYNazike Yıldız
Nazike Yıldız
Aim: The aim of this study was to determine the prevalence of childhood psychopathologies in Turkey. Method: A nation-wide, randomly selected, representative population of 5830 children (6–13 years-old) enrolled as a 2nd,3rd or 4th grade student in 30 cities were evaluated for presence of a psychiatric or mental disorder by a Sociodemographic Form, Kiddie Schedule for Affective Disorders and Schizophrenia for School Age Children-Present and Lifetime Version (K-SADS-PL), and DSM-IV-Based Screening Scale for Disruptive Behavior Disorders in Children and Adolescents scales. Impairment criterion was assessed via a 3 point-Likert scale by the parent and the teacher independently. Results: Overall prevalence of any psychopathology was 37.6% without impairment criterion, and 17.1% with impairment criterion. Attention-deficit hyperactivity disorder was the most frequent diagnosis, followed by anxiety (19.5% and 16.7% without impairment, 12.4% and 5.3% with impairment, respectively). Lower education level and presence of a physical or psychiatric problem of the parents were independent predictors of any psychopathology of the offspring. Conclusion: This is the largest and most comprehensive epidemiological study to determine the prevalence of psychopathologies in children and adolescents in Turkey. Our results partly higher than, and partly comparable to previous national and international studies. It also contributes to the literature by determining the independent predictors of psychopathologies in this age group.

1 July 2012 in Comprehensive Psychiatry
Verified
Journal Article
Closed access
CCCem Cerit
Cem Cerit
AFArzu Filizer
Arzu Filizer
ÜTÜmit Tural
Ümit Tural
ATAli Evren Tufan
Ali Evren Tufan

1 December 2004 in Journal of Traumatic Stress
Verified
Journal Article
Closed access
PDF file
ÜTÜmit Tural
Ümit Tural
BCBülent Coşkun
Bülent Coşkun
EÖEmin Önder
Emin Önder
AÇAytül Çorapçioǧlu
Aytül Çorapçioǧlu
MYMustafa Yildiz
Mustafa Yildiz
GAGaye Aybar
Gaye Aybar

11 February 2020 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
ÜTÜmit Tural
Ümit Tural
DIDan Vlad Iosifescu
Dan Vlad Iosifescu

20 January 2010 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Open access
PDF file
ÜTÜmit Tural
Ümit Tural
EÖEmin Önder
Emin Önder
Aim:  The aim of the present study was to evaluate demographics, clinical features, psychiatric diagnoses and prognosis of neuroleptic malignant syndrome (NMS) reported in Turkey, and to assess their association with mortality.Methods:  Data on all reported cases of NMS in the Turkish Psychiatric Index between 1985 and 2005 were collected. The type, dosage and administration period of neuroleptics, the clinical and laboratory findings; and prognosis were compared in terms of mortality.Results:  Thirty‐six patients with a mean age of 33.67 ± 16.98 years were identified. Fifteen (41.7%) were diagnosed as having schizophrenia or other psychotic disorders and the same number were diagnosed as having affective disorder. Remaining five (13.9%) were diagnosed with other psychiatric disorders and 1 (2.7%) had no psychiatric diagnosis. Twenty‐two (61.1%) of the NMS cases were associated with high potency typical neuroleptics. Association between an atypical antipsychotic and NMS has been reported in one case. NMS appeared within 7 days after initiation of the antipsychotic medication in the majority of samples (n = 19, 52.8%). Several combinations of rescue treatments were used in the majority of cases (n = 19, 52.8%), although bromocriptine (n = 22, 61.1%) was the most frequently preferred rescue treatment for NMS. Benzodiazepines were significantly better than the other treatment options in preventing mortality. Five out of the 36 patients (13.9%) with NMS had died. Age was the only significant independent factor that was associated with mortality.Conclusions:  Benzodiazepines may be included in the treatment of NMS. The mortality rate due to NMS in Turkey was lower than the previously reported rates from other developing countries.